As of 2024-12-15, the Fair Value of Gensight Biologics SA (SIGHT.PA) is -1.39 EUR. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 0.32 EUR, the upside of Gensight Biologics SA is -540.39%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 5Y Avg | |
| Net income | -30.87 | -34.02 | -28.62 | -27.62 | -26.22 | -29.47 |
| YoY growth | 7.72% | -10.19% | 15.87% | 3.47% | 5.08% | 4.39% |
| Market Cap (mil) | 36.41 |
| P/E | |
| Forward P/E |
| EPS | -0.28 |
| Avg earnings growth rate | 4.39% |
| TTM earnings | -32.07 |